Tag:

Bristol-Myers Squibb

Latest Headlines

Latest Headlines

Judge tosses Abilify kickback claims, but puts BMS on notice for firing whistleblowers

Bristol-Myers Squibb and Otsuka won't have to fight claims that they promoted Abilify for off-label uses or used kickbacks to persuade doctors to prescribe the antipsychotic drug. A U.S. judge tossed out those allegations, leveled by a couple of whistleblowers in 2011, for lack of specific evidence.

Opdivo, Praluent and LCZ-696 top a launch crop poised for $27B in sales

What's better than a new drug launch? A launch destined for greatness, of course. For sales and marketing teams, that's about as much job security as you can get. 

Novo Nordisk unloads autoimmune project to Bristol-Myers

Novo Nordisk, in the process of exiting autoimmune R&D, has found a new home for one of its early-stage programs, handing it over to Bristol-Myers Squibb for an undisclosed sum.

Merck's Keytruda bests BMS' Yervoy in head-to-head melanoma trial

Advantage Merck in the melanoma immunotherapy race. The U.S.-based company says its PD-1 drug Keytruda met its goals in a head-to-head study with Bristol-Myers Squibb's Yervoy (ipilimumab), dealing a blow to that company's growing immunotherapy franchise.

Bristol-Myers picks up an autoimmune project as Novo quits the field

Novo Nordisk, not long for the world of autoimmune R&D, has found a new home for one of its early-stage programs, handing it over to Bristol-Myers Squibb for an undisclosed sum.

Bristol-Myers chief's last 'paycheck' as CEO is a doozy at $27M

Bristol-Myers Squibb CEO Lamberto Andreotti has had a nice run at the drugmaker, paywise. And as he prepares to move upstairs to the chairman's office--and eventually out the door--he's going out with a bang. Apparently, a $27 million bang.

Bristol-Myers heads back to the FDA with its long-delayed hep C drug

Bristol-Myers Squibb is finally in line for FDA approval for its once-rejected hepatitis C daclatasvir, angling to take third place among companies with next-generation cures for the virus.

What's the next big biotech target in the multibillion-dollar M&A game?

Now that AbbVie has managed to astonish just about everyone in the biopharma business with its $21 billion takeover of Pharmacyclics, there's been a deluge of speculation over the next big target in the M&A game. Yesterday, Bloomberg 's restless team of deal-watchers proffered Bristol-Myers Squibb as a possibility, seeing as how the Big Biotech is now the clear leader in immuno-oncology, where it could be in line for $15 billion in peak sales.

New Bristol-Myers CEO on tap for $8.7M-plus pay package

Bristol-Myers Squibb's incoming CEO will get quite a raise with his new job. But it's likely to be awhile till Giovanni Caforio, now the company's chief operating officer, sees his pay catch up to that of current chief Lamberto Andreotti.

Opdivo's survival benefit inspired FDA to act fast on NSCLC approval: Pazdur

When Opdivo showed it could prolong the lives of lung cancer patients, Bristol-Myers Squibb quickly broadcast the data. And the pharma world was sufficiently impressed. But the FDA was so impressed with the survival data on the new immunotherapy, it was already working on a new approval for the drug.